For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

Research field guide

The Wegovy pill vs Foundayo: the two GLP-1 weight-loss pills compared

Content updated · how dates work

The Wegovy pill (oral semaglutide) and Foundayo (orforglipron) are the two FDA-approved GLP-1 pills for weight loss. How they differ as drugs, how each is taken, what OASIS 4 and ATTAIN-1 found, side effects, and why there is no head-to-head answer yet.

PepsRadar editorial · November 12, 2026 · Original, AI-assisted guide · Not reviewed by a medical professional

13.6% vs 11.2%: Average weight loss in separate trials: Wegovy pill (OASIS 4) vs top-dose Foundayo (ATTAIN-1)
01

Two pills, two different kinds of drug

Both pills act on the GLP-1 receptor, the same target as the weekly weight-loss injections, but they are built very differently. The Wegovy pill is oral semaglutide, the same peptide used in Wegovy injections, and the tablet also contains an absorption enhancer called salcaprozate sodium (SNAC). Foundayo is orforglipron, a small-molecule, non-peptide drug: a compact chemical rather than a chain of amino acids.

The FDA approval of the Wegovy pill was announced on December 22, 2025, making it the first GLP-1 pill for weight loss. Foundayo followed on April 1, 2026. Both are approved, alongside a reduced-calorie diet and more physical activity, for adults with obesity, or with overweight plus at least one weight-related condition. The Wegovy tablet label also covers lowering the risk of major heart events in adults with established cardiovascular disease and obesity or overweight; the Foundayo label does not.

Source: Wegovy prescribing information, injection and tablets (DailyMed) ↗

Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment ↗

Source: AJMC: FDA approves oral semaglutide for weight loss, December 22, 2025 ↗

Source: FDA: Foundayo approval, April 1, 2026 ↗

Source: Foundayo prescribing information (DailyMed) ↗

02

How they are taken differs

The biggest practical difference is food. The Wegovy pill has to be taken on an empty stomach with only a little plain water, followed by a wait before eating, drinking or taking other pills, because food sharply reduces how much semaglutide is absorbed. The label’s own data show more semaglutide was absorbed when people waited longer.

Foundayo can be taken with or without food, and the FDA noted it does not need to be taken on an empty stomach. With both pills the dose is started low and raised gradually to limit stomach side effects; the exact plan comes from the prescriber and the label.

Source: Wegovy prescribing information, injection and tablets (DailyMed) ↗

Source: Foundayo prescribing information (DailyMed) ↗

Source: FDA: Foundayo approval, April 1, 2026 ↗

03

What the main trials found

OASIS 4 tested the weight-loss dose of the Wegovy pill against placebo in 307 adults without diabetes who had obesity, or overweight with at least one related condition. At 64 weeks, average weight loss was 13.6% on oral semaglutide versus 2.2% on placebo. Novo Nordisk funded the trial.

ATTAIN-1, funded by Eli Lilly, tested three doses of orforglipron against placebo in 3,127 adults with obesity and without diabetes. At 72 weeks, counting everyone who was randomized, average weight loss on the highest dose was 11.2% versus 2.1% on placebo. Our orforglipron explainer covers that trial in more detail.

Source: OASIS 4, Wharton et al., N Engl J Med 2025 ↗

Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment ↗

04

Side effects and stopping treatment

Stomach and gut problems were the main side effects of both. In OASIS 4, gastrointestinal side effects were reported by 74.0% of people on oral semaglutide and 42.2% on placebo; the Wegovy label says 6.9% on the pill and 5.9% on placebo stopped because of side effects. In ATTAIN-1, the gut effects were mostly mild to moderate, and side effects led 5.3 to 10.3% of people on orforglipron to stop, versus 2.7% on placebo.

Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Whether that risk applies to people is unknown.

Source: OASIS 4, Wharton et al., N Engl J Med 2025 ↗

Source: Wegovy prescribing information, injection and tablets (DailyMed) ↗

Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment ↗

Source: Foundayo prescribing information (DailyMed) ↗

05

Is one better? There is no head-to-head trial

The two pills have not been tested against each other in people with obesity. The Wegovy pill’s headline number is higher, but OASIS 4 and ATTAIN-1 enrolled different people, ran for different lengths of time and were very different in size, so the figures are not a direct contest.

One published analysis tried to bridge the gap statistically, using patient-level data from OASIS 4 and summary data from ATTAIN-1. It estimated about 3 percentage points more weight loss with oral semaglutide and higher odds of stopping because of side effects with orforglipron. That is an indirect comparison, not a trial, and it was written mainly by Novo Nordisk employees, with analysis support paid for by Novo Nordisk, the maker of Wegovy. Treat it as a starting point, not a verdict.

Source: Michalak et al., indirect comparison, Diabetes Obes Metab 2026 (Novo Nordisk authors) ↗

Source: OASIS 4, Wharton et al., N Engl J Med 2025 ↗

Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment ↗

06

The bottom line

The choice comes down to trade-offs. The Wegovy pill produced more average weight loss in its own trial and carries a heart-risk indication, but it needs a strict morning routine. Foundayo can be taken with or without food. How each fits with your other medicines, health history and tolerance for side effects is a decision to make with a prescriber. Both are prescription medicines. PepsRadar gives no dosing or treatment advice.

Source: Wegovy prescribing information, injection and tablets (DailyMed) ↗

Source: Foundayo prescribing information (DailyMed) ↗

Continue with the original research

Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

See something wrong on this page? Report a mistake · Corrections